What’s At Stake
What is the case about?
Louisiana challenged the FDA’s current rules governing the abortion drug mifepristone, including allowing the drug to be prescribed through telehealth, mailed to patients, and dispensed through retail pharmacies. After Dobbs v. Jackson Women’s Health Organization returned abortion policy to the states, the Biden administration’s FDA expanded access to chemical abortion by permanently removing the longstanding in-person dispensing requirement and allowing mifepristone to be mailed across state lines. Louisiana and other states challenged those changes, arguing they undermine state abortion laws and exceed the FDA’s authority.
The Fifth Circuit temporarily reinstated the older in-person dispensing requirements, prohibiting mail-order distribution nationwide while the case proceeds. Danco and GenBioPro, the manufacturers of mifepristone, filed emergency applications asking the Supreme Court to block the Fifth Circuit’s order. In a 7–2 decision, SCOTUS granted the emergency stay, allowing the FDA’s current rules to remain in place while litigation continues. Justices Thomas and Alito dissented.
Who is affected and how?
This case affects all states attempting to regulate abortion within their borders. Because the FDA’s drug regulations apply nationwide, the Fifth Circuit’s order would have immediately changed access to mifepristone across the country, including in states with differing abortion laws.
Why does it matter?
The case raises major constitutional and administrative law questions about the scope of federal agency power and judicial review. It also continues the broader national legal debate over abortion access after Dobbs. Beyond abortion itself, the litigation could shape how much deference courts give federal agencies making scientific and regulatory decisions affecting public health and safety.
Our Take
The Supreme Court’s order was procedural and temporary, not a final ruling on the merits. The case continues in the Fifth Circuit and could return to the Supreme Court for full review. But the broader issue remains unresolved: whether federal agencies can use regulatory power to undermine state abortion policies after Dobbs expressly returned those decisions to the states and the people.
